These three studies represent a fundamental starting point to further understand the role of EVs in target-therapy resistance mechanisms in melanoma and they prove the fundamental role of EVs in the development of melanoma-resistance regarding the use of BRAF-inhibitors that are worth further investigations. The gene discussed is BRAF; the disease is melanoma.